All News

Your daily dose of the clinical news you may have missed.

Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.

Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.

Obesity rates in the US over the 3 decades rose from 11.5% to 21.7% among boys and from 11.6% to 19.4% among girls. US men ranked 10th highest for obesity in 2022.

Your daily dose of the clinical news you may have missed.

The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.

Which city has the highest depression rate? Or the fewest work hours? Find the answers and more insights from a nationwide analysis, here.

The accuracy of the test in detecting Aβ and tau pathology underscores its potential to become an accessible and cost effective tool for Alzheimer diagnosis.

The risk for cardiovascular outcomes increased with more frequent reported cannabis use per month, according to results from a large national study.

Your daily dose of the clinical news you may have missed.

Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.

Your daily dose of the clinical news you may have missed.

Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.

Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.

Atogepant once daily reduced mean monthly headache days in adults for whom up to 4 classes of oral migraine preventives were ineffective.

AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.

The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.

"Viral reservoirs" in human tissue may preserve the SARS-CoV-2 virus, provoking an immune response that could drive long COVID-associated symptoms.